Intervention not reported
Progression‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma
The intervention showed no clear difference in progression‐free survival (high certainty).
1 finding from 1 review
Intervention not reported
Non‐hematologic toxicity grade 3 to 4 · people with non‐rhabdomyosarcoma soft tissue sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Health‐related quality of life · people with non‐rhabdomyosarcoma soft tissue sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Mortality (all cause) Long‐term · people with chronic ischaemic heart disease and congestive heart failure
The intervention may leads to lower mortality (all cause) Long‐term (low certainty).
1 finding from 1 review
Intervention not reported
Periprocedural adverse events · people with chronic ischaemic heart disease and congestive heart failure
1 finding from 1 review
Intervention not reported
Non‐fatal myocardial infarction Long‐term · people with chronic ischaemic heart disease and congestive heart failure
The intervention may leads to lower non‐fatal myocardial infarction Long‐term (low certainty).
1 finding from 1 review
Intervention not reported
Rehospitalisation due to heart failure Long‐term · people with chronic ischaemic heart disease and congestive heart failure
The intervention showed no clear difference in rehospitalisation due to heart failure Long‐term (low certainty).
1 finding from 1 review
Intervention not reported
Arrhythmias Long‐term · people with chronic ischaemic heart disease and congestive heart failure
The intervention may leads to lower arrhythmias Long‐term (low certainty).
1 finding from 1 review
Intervention not reported
Composite MACE Long‐term · people with chronic ischaemic heart disease and congestive heart failure
The intervention showed no clear difference in composite MACE Long‐term (low certainty).
1 finding from 1 review
Intervention not reported
LVEF (%) measured by MRI Long‐term · people with chronic ischaemic heart disease and congestive heart failure
1 finding from 1 review
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in numbers of participants with at least 1 clinically significant… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in number of participants with WHO Grade 3 or 4 bleeding up to 30 days… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in time to first bleeding episode (days) compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in mortality from all causes up to 30 days from study entry compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with prophylactic platelet transfusions with standard‐dose schedule (moderate certainty).
1 finding from 1 review
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with high‐dose schedule (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with high‐dose schedule (low certainty).
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review